Table 3.
Patient demographics (concordant grade 2 tumor cohort).
| Characteristics | Before matching |
After matching |
||||
|---|---|---|---|---|---|---|
| |
OVCA (+) |
OVCA (−) |
P-value | OVCA (+) |
OVCA (−) |
P-value |
| Number | n = 155 | n = 36,572 | n = 155 | n = 155 | ||
| Age | 50.9 (± 10.1) | 63.5 (± 11.8) | <0.001 | 50.9 (± 10.1) | 52.8 (± 12.2) | 0.59 |
| <40 | 16 (10.3%) | 923 (2.5%) | 16 (10.3%) | 19 (12.3%) | ||
| 40–49 | 62 (40.0%) | 3,069 (8.4%) | 62 (40.0%) | 52 (33.5%) | ||
| 50–59 | 50 (32.3%) | 9,489 (25.9%) | 50 (32.3%) | 50 (32.3%) | ||
| ≥60 | 27 (17.4%) | 23,091 (63.1%) | 27 (17.4%) | 34 (21.9%) | ||
| Race/ethnicity | 0.15 | 0.96 | ||||
| White | 130 (83.9%) | 29,427 (80.5%) | 130 (83.9%) | 125 (80.6%) | ||
| Black | 2 (1.3%) | 1,997 (5.5%) | 2 (1.3%) | 3 (1.9%) | ||
| Hispanic | 14 (9.0%) | 2,655 (7.3%) | 14 (9.0%) | 16 (10.3%) | ||
| Asian | 8 (5.2%) | 1,903 (5.2%) | 8 (5.2%) | 10 (6.5%) | ||
| Others | 1 (0.6%) | 590 (1.6%) | 1 (0.6%) | 1 (0.6%) | ||
| Year at diagnosis | 0.09 | 0.59 | ||||
| 1973–1979 | 2 (1.3%) | 948 (2.6%) | 2 (1.3%) | 4 (2.6%) | ||
| 1980–1989 | 7 (4.5%) | 3,854 (10.5%) | 7 (4.5%) | 11 (7.1%) | ||
| 1990–1999 | 35 (22.6%) | 8,294 (22.7%) | 35 (22.6%) | 34 (21.9%) | ||
| 2000–2009 | 80 (51.6%) | 16,377 (44.8%) | 80 (51.6%) | 83 (53.5%) | ||
| 2010–2013 | 31 (20.0%) | 7,099 (19.4%) | 31 (20.0%) | 23 (14.8%) | ||
| Marital status | <0.001 | 0.68 | ||||
| Single | 50 (32.3%) | 5,032 (13.8%) | 50 (32.3%) | 47 (30.3%) | ||
| Married | 79 (51.0%) | 19,724 (53.9%) | 79 (51.0%) | 76 (49.0%) | ||
| Others | 26 (16.8%) | 11,816 (32.3%) | 26 (16.8%) | 32 (20.6%) | ||
| Registry area | 0.11 | 0.76 | ||||
| West | 76 (49.0%) | 18,553 (50.7%) | 76 (49.0%) | 81 (52.3%) | ||
| Central | 29 (18.7%) | 8,660 (23.7%) | 29 (18.7%) | 30 (19.4%) | ||
| East | 50 (32.3%) | 9,359 (25.6%) | 50 (32.3%) | 44 (28.4%) | ||
| Stage | 0.018 | 0.99 | ||||
| IA | 126 (91.3%) | 26,739 (73.1%) | 126 (91.3%) | 126 (91.3%) | ||
| IB | 14 (9.0%) | 6,464 (17.7%) | 14 (9.0%) | 14 (9.0%) | ||
| I NOS | 15 (9.7%) | 3,372 (9.2%) | 15 (9.7%) | 15 (9.7%) | ||
| Size | 0.65 | 0.49 | ||||
| ≤2.0 cm | 16 (10.3%) | 3,881 (10.6%) | 16 (10.3%) | 23 (14.8%) | ||
| >2.0 cm | 64 (41.3%) | 13,782 (37.7%) | 64 (41.3%) | 60 (38.7%) | ||
| Unknown | 75 (48.4%) | 18,909 (51.7%) | 75 (48.4%) | 72 (46.5%) | ||
| Lymphadenectomy | <0.001 | 0.37 | ||||
| Not performed | 43 (27.7%) | 14,290 (39.1%) | 43 (27.7%) | 36 (23.2%) | ||
| Performed | 108 (69.7%) | 19,465 (53.2%) | 108 (69.7%) | 111 (71.6%) | ||
| Unknown | 4 (2.6%) | 2,817 (7.7%) | 4 (2.6%) | 8 (5.2%) | ||
| Radiotherapy | 0.02 | 0.78 | ||||
| No | 133 (85.8%) | 27,904 (76.3%) | 133 (85.8%) | 137 (884%) | ||
| Yes | 20 (12.9%) | 7,671 (21.0%) | 20 (12.9%) | 16 (10.3%) | ||
| Unknown | 2 (1.3%) | 997 (2.7%) | 2 (1.3%) | 2 (1.3%) | ||
Number (%) per column or mean (±standard deviation) is shown. P-values are results of univariable analysis, and significant P-values are emboldened. Abbreviations: OVCA synchronous stage I endometrioid ovarian cancer; and NOS, not otherwise specified.